# Diabetes Research Hub — Monitor Report

**Run date:** 2026-05-06
**Run type:** Scheduled automated review (read-only — no files modified)
**Workspace:** Diabetes_Research

---

## File System Status

The daily snapshot pipelines have **not yet run today**. All "latest" data files were last refreshed on 2026-05-05 (~24 h old). The literature gap analysis was re-run yesterday, so gap data is current.

| File | Last modified | Age | Status |
|---|---|---|---|
| hub_monitor_report.md | 2026-05-05 07:05 | ~24 h | OK (pre-today's run) |
| clinical_trials_latest.json | 2026-05-05 07:05 | ~24 h | OK (today's pull pending) |
| pubmed_recent_latest.json | 2026-05-05 07:05 | ~24 h | OK (today's pull pending) |
| clinical_trials_summary.md | 2026-05-05 | ~24 h | OK |
| pubmed_recent_summary.md | 2026-05-05 | ~24 h | OK |
| literature_gap_report.md | 2026-05-05 08:12 | ~22 h | **OK — re-run yesterday** (resolves prior staleness flag) |
| literature_gap_data.json | 2026-05-05 (regenerated) | <2 d | OK (date-range coverage 2020/01/01 → 2026/04/20) |
| agent_state.json | 2026-05-04 08:14 | 2 d | OK |
| citation_validation.json | 2026-05-04 08:13 | 2 d | OK |
| evidence_network.json | 2026-05-04 08:13 | 2 d | OK |
| pmid_verification.json | 2026-05-04 08:13 | 2 d | OK |
| Diabetes_Research_Tracker.xlsx | 2026-04-17 | 19 d | **Aging — manual update overdue** (currently locked open per .lock file) |

The hub_monitor.py scan from 2026-05-05 07:05 reported 793 total files tracked, 4 new, 31 modified, 0 removed, with 561 result files older than 14 days (almost entirely the dated daily snapshots that are intentionally archival). No new actionable staleness has appeared since yesterday's report.

---

## Clinical Trial Changes

**Source:** clinical_trials_latest.json (783 trials; ClinicalTrials.gov API v2, snapshot dated 2026-05-05).

### Category counts (no change since 2026-05-05)

| Category | Count |
|---|---|
| T1D Cure & Cell Therapy | 151 |
| T1D Immunotherapy & Prevention | 71 |
| T2D Novel Therapies (Phase 2-3) | 139 |
| Diabetes Technology (Devices) | 222 |
| Diabetes Recently Completed with Results | 272 |

### Status mix
RECRUITING 262 · COMPLETED 272 · NOT_YET_RECRUITING 132 · ACTIVE_NOT_RECRUITING 111 · ENROLLING_BY_INVITATION 6.

### Snapshot diff captured in yesterday's run (2026-05-04 → 2026-05-05)

5 new trials, 0 removed, 0 status changes, 0 newly posted results. Highest-priority addition was **NCT07564414** (Novo CagriSema vs. Semaglutide head-to-head, Phase 3, NOT_YET_RECRUITING). Today's diff cannot be computed because the 2026-05-06 snapshot has not yet been pulled.

### Key Phase-3 trials still on the watchlist (unchanged)

- **VX-880 / zimislecel** (Vertex) — NCT06832410 and NCT04786262 both Phase 3 RECRUITING; encapsulated sister candidate **VX-264** (NCT05791201) ACTIVE_NOT_RECRUITING.
- **Baricitinib** (Eli Lilly) — NCT07222137 (delay stage 3 in adults) and NCT07222332 (preserve pediatric β-cell function) Phase 3 RECRUITING.
- **Teplizumab Phase 3** — NCT07088068 RECRUITING (placebo-controlled). Recent FDA action (Tzield pediatric stage-3-delay label expansion, 2026-04-22) and the British BSPED/ABCD consensus statement (PMID 42051156, 2026-04-29) keep this the highest-leverage T1D file in our hub.
- **Diamyd** — NCT05018585 Phase 3 RECRUITING.
- **Insulin icodec** — NCT07076199 Phase 3 RECRUITING (now contextualized by the FDA Awiqli approval — see Breaking News).
- **Tirzepatide in T1D** — NCT07284511 (Phase 2/3 RECRUITING) plus Lilly companions NCT06914895 and NCT06962280.
- **Retatrutide** — NCT06260722 (vs. semaglutide) and NCT05929079 (monotherapy) ACTIVE_NOT_RECRUITING; the **TRANSCEND-T2D-1** Phase 3 readout (announced this week) has not yet posted results to the database.
- **CagriSema (NCT07564414)** — newly added yesterday, not yet recruiting; expands Novo's CagriSema phase-3 program with semaglutide as comparator.

273 trials in the dataset have results posted; **0 new postings** in the past 7-day window.

---

## PubMed Highlights

**Source:** pubmed_recent_latest.json (146 unique papers across 16 alert domains; 30-day lookback; last refreshed 2026-05-05 07:05).

### Cross-domain papers (highest priority — 9 total, unchanged from yesterday)

These appear in 2+ alert domains and remain the highest-value signals until today's pull rotates them:

1. **PMID 42051156** — *Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society* (Diabetic Medicine, 2026-04-29). Domains: T1D Immunotherapy + Key Therapy: teplizumab. **Top priority — directly relevant to Tier 1 Clinical Trial Intelligence and the new pediatric Tzield label.**
2. **PMID 42082522** — *Sex-specific microbial and tryptophan signatures of depression implicate archaeal methanogens and indole-3-acetic acid only in women* (NPJ Biofilms and Microbiomes, 2026-05-04). Domains: Diabetes AI/ML + Diabetes Microbiome.
3. **PMID 42076618** — *A Novel Convolutional Neural Network for Explainable Diabetic Retinopathy Detection and Grade Identification* (Sensors, 2026-04-18). Domains: Diabetes AI/ML + Diabetes Complications.
4. **PMID 42078397** — *A loss-of-function variant in [gene]* (medRxiv preprint, 2026-04-20). Domains: T2D Remission + Diabetes Gene Therapy.
5. **PMID 42074825** — *Renal Fat Fraction and Early Biomarkers of Kidney Injury in T2D* (J Clin Med, 2026-04-15). Domains: T2D GLP-1 New + Diabetes Biomarker.
6. **PMID 42070230** — *Viscous DES-AAV-Foxo1 Delivery System for Corneal Endothelial Dysfunction* (Adv Sci, 2026-05-03). Domains: Diabetes Gene Therapy + Diabetes Multi-Omics.
7. **PMID 42063171** — *miR-103a-3p contributes to diabetic retinopathy progression via suppressing MFN2*. Domains: T2D Remission + Diabetes Complications.
8. **PMID 42046753** — *Effect of breaking up sitting on glucose management* in T1D + closed-loop populations.
9. **PMID 42034968** — *Bone marrow-derived cells in experimental autoimmune T1D*. Domains: T1D Stem Cell Cure + T1D Immunotherapy.

### Key-therapy mention counts (past 30 days, abstract search)

| Therapy | Papers | Notable |
|---|---|---|
| dapagliflozin | 24 (5 papers titled) | Background-volume drug; one new mouse mechanism paper (cardiac fibrosis in HIV, AIDS journal, 2026-06-01). |
| orforglipron | 4 | PK bioequivalence (PMID 41994902), oral-vs.-SC GLP-1 cardiometabolic NMA (PMID 41992023). |
| icodec | 4 | China cost-utility (PMID 41705603); efsitora-alfa review (PMID 42048049). **Now reinforced by FDA approval of Awiqli.** |
| teplizumab | 3 | British BSPED/ABCD consensus + two real-world papers (Diabetologia, DOM). |
| baricitinib | 2 | JCI Insight islet-tolerance conditioning paper (PMID 42013280) is the most strategically relevant. |
| retatrutide | 2 | Adipose-brain axis review and GIPR:GCGR co-agonism in obese rodents. **TRANSCEND-T2D-1 Phase 3 topline now public — full PubMed coverage expected post-ADA 2026 Scientific Sessions in June.** |
| zimislecel | 0 | No PubMed mentions despite VX-880 Phase 3 enrolling. |
| CagriSema | 0 | No PubMed mentions; new trial NCT07564414 added yesterday. |

Domain-volume distribution is unchanged: AI/ML (185), Biomarker (134), Microbiome (126), and T2D GLP-1 New (122) lead the 30-day window. **GLP-1 Pharmacogenomics (1 paper)**, **LADA (2 papers)**, and **Drug Repurposing (4 papers)** remain the consistently sparse domains — three of these align with priority gaps in our literature_gap_data.json analysis, reinforcing that they are real opportunities, not search artifacts.

---

## Gap Analysis Summary

**Source:** literature_gap_report.md (regenerated 2026-05-05 08:12, BRONZE evidence level). Date-range coverage 2020-01-01 → 2026-04-20.

### Top 5 ranked gaps (Gap Score 100.0)

1. **Beta Cell Regen × Health Equity** (0 joint papers; expected ~1,615) — equity analysis of regenerative cell therapies essentially absent.
2. **Insulin Resistance × Islet Transplant** (1 joint paper; expected ~2,138) — IR in transplant recipients affects graft survival but is barely studied.
3. **Islet Transplant × Drug Repurposing** (0 joint papers) — no computational screen of existing immunosuppressants/metabolic agents for islet protection.
4. **Islet Transplant × Health Equity** (0 joint papers) — center-restricted therapy with no access-equity literature.
5. **Gene Therapy × LADA** (0 joint papers) — LADA's autoimmune mechanism is a plausible gene-therapy target with no crossover.

### Tier 1 alignment (per RESEARCH_DOCTRINE.md)

- **Drug Repurposing Computational Screening (Tier 1, score 18/20)** → directly addresses gap #3.
- **Literature Synthesis & Gap Analysis (Tier 1, score 19/20)** → gaps #1, #4, and the broader Health Equity intersections.
- **Epidemiological Data Analysis / Health Equity (Tier 1, score 17/20)** → gaps #1 and #4.
- **Multi-Omics Biomarker Integration (Tier 1, score 19/20)** → gap #2 (IR × Islet Transplant) is amenable to biomarker-based recipient stratification.

The Beta Cell Regen × Health Equity gap (#1) and the two Islet Transplant cross-cuts (#3, #4) remain the strongest immediate computational-contribution candidates. All gap classifications are BRONZE pending domain-expert review per the Research Doctrine.

---

## Breaking News (web check — last 7 days)

Three items not present in yesterday's report; the rest of this week's diabetes news is consistent with what is already captured.

- **2026-04-29 — FDA approval: Langlara (insulin glargine-aldy).** Long-acting interchangeable biosimilar to Lantus for diabetes mellitus. Adds to the now-rapid biosimilar approval cadence (first generic dapagliflozin 2026-04-07, Awiqli 2026-03-26). Tracker entry recommended; evidence level BRONZE pending the FDA letter and label.
- **2026-05-04 — Novo Nordisk launch: oral Ozempic (semaglutide tablets, 1.5 mg / 4 mg / 9 mg) becomes commercially available in the US.** This is a *launch* of an already-approved product, not a new approval, but is operationally relevant to T2D GLP-1 New tracking and likely to trigger a wave of real-world utilization papers over the next 30–60 days.
- **2026-04-30 (approximately) — Eli Lilly TRANSCEND-T2D-1 (retatrutide) Phase 3 topline.** Met primary HbA1c endpoint and all key secondary endpoints at 40 weeks vs. placebo in T2D. Detailed data deferred to the ADA 2026 Scientific Sessions (June). Companion to the previously logged retatrutide TRANSCEND program.

Already in our dataset (no new action): **survodutide SYNCHRONIZE-1** Phase 3 readout (BI, 2026-04-28); **Tzield (teplizumab)** pediatric label expansion (Sanofi, 2026-04-22); **orforglipron / Foundayo** FDA approval (2026-04-01, fastest NME approval since 2002); first generic **dapagliflozin** tablets approved (2026-04-07).

Note also: the **MannKind Afrezza (inhaled insulin)** sNDA for pediatric T1D/T2D expansion has a **PDUFA date of 2026-05-29** — worth pre-staging a tracker entry now so the action-day result lands cleanly.

---

## Recommended Actions

Ordered by priority. Items 1 and 2 are time-sensitive.

1. **Run today's daily pulls** — the 2026-05-06 snapshots have not been generated. Execute, in order:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   - `python hub_monitor.py`
   This will populate today's diffs and unblock automated tracking.
2. **Update Diabetes_Research_Tracker.xlsx** (now 19 days stale, file currently locked open per `.~lock`):
   - Add **NCT07564414** (Novo CagriSema vs. Semaglutide, Phase 3, NOT_YET_RECRUITING) — added to feed yesterday.
   - Add **NCT07563699** (Mapi Pharma semaglutide depot, Phase 1/2) — added yesterday.
   - Update statuses for **NCT07321678** (RECRUITING → ACTIVE_NOT_RECRUITING) and **NCT07355270** (NOT_YET_RECRUITING → RECRUITING).
   - Add external Phase 3 readouts not in the ClinicalTrials.gov pull: **survodutide SYNCHRONIZE-1** (BI, 2026-04-28) and **retatrutide TRANSCEND-T2D-1** (Lilly, ~2026-04-30) — both BRONZE pending peer-reviewed publication.
   - Add FDA approvals: **Langlara** (insulin glargine biosimilar, 2026-04-29) and pre-stage **Afrezza** pediatric PDUFA (2026-05-29).
3. **Review cross-domain paper PMID 42051156** (teplizumab British BSPED/ABCD consensus) — directly relevant to T1D Immunotherapy + Tier 1 Clinical Trial Intelligence and to the recent pediatric Tzield label expansion. Strong candidate for inclusion in the next Research_Findings_Summary.md update.
4. **Initiate Tier 1 contribution work on Islet Transplant × Drug Repurposing** (gap #3) — zero joint publications, full alignment with the 18/20 Tier 1 area, and computationally feasible with existing OpenTargets / DrugBank access. The JCI Insight baricitinib islet-tolerance paper (PMID 42013280) is a strong anchor for the literature scaffold.
5. **No action required** for: literature_gap_report.md (re-run yesterday), agent_state.json, evidence_network.json, dashboards (all current).

---

*Generated by automated monitor task — read-only run. Evidence-level annotations follow Research Doctrine v1.0; all new external-source claims (FDA approvals, Phase 3 toplines, breaking news) marked BRONZE pending peer-reviewed corroboration.*
